Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Nexell Therapeutics

This article was originally published in The Gray Sheet

Executive Summary

Nexell Therapeutics: Baxter/VimRx cell therapy joint venture submits a premarket approval application supplement to a pending PMA for the Isolex 300 semi-automated stem cell selection system. The supplement requests FDA review of the firm's Isolex 300i fully automated system, which, like the Isolex 300, is intended for enrichment of CD34+ cells and the reduction of non-target (non CD34+) cells in cryopreserved autologous peripheral blood stem cell products that are reinfused into patients undergoing autologous peripheral blood transplantation. The transplantation procedure is used to restore a patient's blood and immune system following high-dose chemotherapy. Data in support of the PMA supplement was submitted to FDA from three separate trials, one of which involved 114 patients (92 randomized) with high risk or advanced breast cancer. During a review of the original Isolex submission in July, FDA's Biological Response Modifiers Advisory Committee did not take a formal vote on the PMA, but did agree that study data demonstrated efficacy ("The Gray Sheet" July 28, 1997, p. 8)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009784

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel